Inhibition of proliferation, invasion, and migration of prostate cancer cells by downregulating elongation factor-1alpha expression.
Overexpression of elongation factor-1alpha (EF-1alpha) has been reported to contribute to the development and progression of various cancers. However, its role in prostate cancer (PCa) still remains poorly understood. In the present study, we investigate the influence of EF-1alpha in Du145, a high-grade metastatic PCa cell line, and demonstrate that EF-1alpha plays an essential role in cellular properties associated with tumor progression, namely cell proliferation, invasion, and migration. In this study, EF-1alpha expression in human PCa cell line Du145 was reduced by RNA interference (RNAi) technology, and the proliferation, invasion, and migration of EF-1alpha-reduced Du145 cells were examined. We also detected an EF-1alpha expression pattern in 20 pairs of primary PCa samples and their corresponding normal tissues. Expression of EF-1alpha was detectable in four PCa cell lines (22RV1, LnCap, Du145, and PC3), indicating its possible role in pathogenesis of PCa. RNAi-mediated knockdown of EF-1alpha expression in Du145 cells, which expressed the highest level of EF-1alpha among four PCa cell lines, led to a decrease in proliferation. Similarly, suppression of EF-1alpha inhibited Du145 cell migration and invasion through a basement membrane substitute. Furthermore, we found that the normal prostate tissues showed a relatively low level of EF-1alpha expression, whereas PCa tissues demonstrated significantly higher expression levels of EF-1alpha (P < 0.001). Taken together, these findings support the hypothesis that EF-1alpha affects multiple processes involved in tumor progression, and identify EF-1alpha as a potential therapeutic target.
Zhu
Gang
G
Department of Urology, Beijing Hospital MH, Beijing, China.
Yan
Wei
W
He
Hui-chan
HC
Bi
Xue-cheng
XC
Han
Zhao-dong
ZD
Dai
Qi-shan
QS
Ye
Yong-kang
YK
Liang
Yu-xiang
YX
Wang
Jianye
J
Zhong
Weide
W
D048708:Cell Growth Processes / Q000235:genetics; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics; D015536:Down-Regulation; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D009361:Neoplasm Invasiveness; D020648:Peptide Elongation Factor 1 / Q000235:genetics / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000235:genetics; D015203:Reproducibility of Results
D020648:Peptide Elongation Factor 1; D034741:RNA, Small Interfering
J Biol Chem. 1993 Jan 5;268(1):392-8
8380160
Prostate. 2002 Jun 1;51(4):247-55
11987153
Anal Biochem. 1976 May 7;72:248-54
942051
J Surg Res. 2010 May 15;160(2):260-7
19286191
Oral Oncol. 2006 Mar;42(3):240-56
16266819
Prostate. 2006 Nov 1;66(15):1641-52
16927306
Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4991-5
2052582
Trends Biochem Sci. 1995 May;20(5):169-70
7610475
Science. 2002 Jan 25;295(5555):694-7
11809977
Cancer Res. 2006 Sep 15;66(18):9065-73
16982748
Nature. 2001 Jan 18;409(6818):363-6
11201747
Nature. 2001 May 17;411(6835):375-9
11357145
Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10233-8
9294193
Pathol Oncol Res. 2009 Sep;15(3):369-74
19048397
J Biol Chem. 1989 Dec 5;264(34):20518-25
2511205
J Biol Chem. 1983 Jan 10;258(1):24-6
6336747
Nature. 2001 May 24;411(6836):494-8
11373684
Cancer Res. 1991 Sep 15;51(18 Suppl):5054s-5059s
1884381
Hum Genet. 1987 Apr;75(4):339-44
3570288
Nature. 2001 Mar 1;410(6824):24-5
11242022
Nature. 2002 Jul 11;418(6894):244-51
12110901
Clin Cancer Res. 2001 Jul;7(7):1987-91
11448915
Nature. 1998 Feb 19;391(6669):806-11
9486653
J Biol Chem. 1995 Jun 23;270(25):15222-30
7797506
Science. 2000 Nov 10;290(5494):1159-62
11073454
N Engl J Med. 2003 Jul 24;349(4):366-81
12878745
Cancer Res. 2006 Mar 15;66(6):3071-7
16540656
Annu Rev Cell Biol. 1988;4:649-86
2848555
J Biol Chem. 1990 Feb 5;265(4):2286-91
2404981
J Cell Biol. 1994 Aug;126(4):863-76
7914201
Cell Motil Cytoskeleton. 1991;20(4):279-88
1666339